Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday, February 12, 2024.
Related news for (VCEL)
- Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance
- Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results
- Vericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
- vericel announces fda approval and commercial availability of maci arthro
- vericel announces fda approval of nexobrid for the treatment of pediatric patients with severe thermal burns